This company listing is no longer active
DDDD Stock Overview
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
4D pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.17 |
| 52 Week High | UK£0.77 |
| 52 Week Low | UK£0.14 |
| Beta | 2.74 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -54.42% |
| 3 Year Change | -83.26% |
| 5 Year Change | -92.83% |
| Change since IPO | -90.34% |
Recent News & Updates
Shareholder Returns
| DDDD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -0.7% |
| 1Y | -54.4% | -29.4% | -1.8% |
Return vs Industry: DDDD underperformed the UK Biotechs industry which returned -24.7% over the past year.
Return vs Market: DDDD underperformed the UK Market which returned -3.7% over the past year.
Price Volatility
| DDDD volatility | |
|---|---|
| DDDD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DDDD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DDDD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 106 | Duncan Peyton | www.4dpharmaplc.com |
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn’s disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis.
4D pharma plc Fundamentals Summary
| DDDD fundamental statistics | |
|---|---|
| Market cap | UK£30.04m |
| Earnings (TTM) | -UK£26.50m |
| Revenue (TTM) | UK£595.83k |
50.4x
P/S Ratio-1.1x
P/E RatioIs DDDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DDDD income statement (TTM) | |
|---|---|
| Revenue | US$718.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$718.00k |
| Other Expenses | US$32.66m |
| Earnings | -US$31.94m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,448.19% |
| Debt/Equity Ratio | 36.5% |
How did DDDD perform over the long term?
See historical performance and comparison